From Data to Outcomes: Empowering the healthcare industry to access, analyze, and use deeper data in a more robust and clinically meaningful way.
Price $12,000 | 12 month subscription available.
This product contains records for a selection of 10,000 synthetic patient records from 2018. This includes de-identified demographics, diagnoses, procedures, medications and lab test results. These data are available only for specific medical research purposes that must be approved in advance of delivery and use.
Price $999 | 12 month subscription available.
This product provides switching patterns between different biologic disease-modifying antirheumatic drugs (bDMARDs) during first, second, and third lines of bDMARD therapy. All patients in this dataset received treatment with adalimumab (Humira), the best-selling drug in the United States since 2012. Additional datasets and summaries - including focus on other drugs, additional lines of therapy, and specific time periods - are available upon request.
showing 1 - 2